Labcorp — Apr 30, 2026 release

Our investments in advanced technologies, including robotics and AI, are improving the customer experience and transforming the way we operate. Driven by continued progress across our strategic priorities, we are raising our full year Adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13.” 1 Labcorp continues to advance its strategic priorities: Be a partner of choice for health systems and regional and local laboratories: • Announced a nationwide strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to expand access to cutting-edge diagnostics for pediatric patients. • Completed the acquisition of select assets of Crouse Health’s Laboratory Alliance of Central New York and executed an agreement with Crouse Health to manage their inpatient labs. Lead in specialty testing: • Announced a collaboration with Illumina to expand access to advanced genomic testing in oncology to deliver more precise biomarker insights. • Expanded nationwide access to the first FDA-approved companion diagnostic that helps identify patients with platinum‑resistant ovarian cancer who may benefit from Merck’s KEYTRUDA® and KEYTRUDA QLEX™. • Launched the Labcorp Fentanyl Visual Urine Test, an FDA‑cleared rapid screening test that delivers results in just 10 minutes and assesses possible fentanyl exposure for up to 48 hours. Shape our future through technology and innovation: • Launched an AI-powered, real-world data platform